MedTrace Logo

Investigating Patient Satisfaction With Oral Anti-Cancer Treatment

NCT02247583 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2014-09-25

No results posted yet for this study

Summary

Prospective non-interventional non-controlled multicenter observational study to evaluate aspects of pharmaceutical care in patients with advanced renal cell carcinoma treated with an oral anti-cancer drug.

The main objective of this study is to evaluate the patient perspective in the treatment of advanced renal cell carcinoma with an oral anti-cancer drug.

The following aspects will be investigated:

* Intrinsic desire for information about treatment.
* Patient satisfaction with treatment information.
* Patient satisfaction with treatment.
* Medication adherence.
* Health-related quality of life.
* The role of different health care professionals in the treatment of RCC with oral drugs

This study should reveal information necessary for the development of pharmacotherapeutic care concepts that meet the needs of cancer patients treated with an oral anti-cancer drug over a long period.

Conditions

Sponsors & Collaborators

  • Flemish League Against Cancer

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • Novartis

    collaborator INDUSTRY

  • GlaxoSmithKline

    collaborator INDUSTRY

  • KU Leuven

    lead OTHER

Principal Investigators

  • Veerle Foulon, Professor · Katholieke Universiteit Leuven - Klinische Farmacologie en Farmacotherapie

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02247583 on ClinicalTrials.gov